IDL Diagnostics AB

As of June 30, 2026, IDL Diagnostics AB carries a market capitalization of 96.75M, placing it among publicly traded companies globally. Its enterprise value stands at 73.59M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

IDL Diagnostics AB's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, IDL Diagnostics AB has 230.36M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.64, and the price-to-book ratio stands at 0.65.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.25 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 73.59M versus a market cap of 96.75M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, IDL Diagnostics AB maintains a current ratio of 3.32, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.20, indicating elevated leverage, while an interest coverage ratio of -9.96 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, IDL Diagnostics AB posted a negative return on equity (ROE) of -3.64, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -3.12, reflecting losses generated across the asset base. The company generates approximately 2.48M in revenue per employee across its workforce of 23.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.15 indicates how many times IDL Diagnostics AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, IDL Diagnostics AB's stock has declined approximately 11.76% over the past 52 weeks. The 50-day moving average sits at 0.38, while the 200-day moving average is 0.38.

Over the twelve months ended June 30, 2026, IDL Diagnostics AB generated 58.97M in revenue and converted that into -4.41M in net income, yielding earnings per share of -0.02. EBITDA reached -4.32M, while operating income came in at -4.32M.

As of June 30, 2026, IDL Diagnostics AB holds 35.31M in cash and equivalents against 12.16M in total debt, resulting in a net debt position of -35.31M. Total book value stands at 148.29M, with working capital of 39.05M providing operational flexibility.

IDL Diagnostics AB produced -5.51M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, IDL Diagnostics AB posted a gross margin of 58.52, reflecting its pricing power and cost economics. The operating margin of -7.33 and net profit margin of -7.48 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -5.61: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches - -, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to IDL Diagnostics AB shareholders.

IDL Diagnostics AB's most recent stock split took place on January 25, 2022 with a 500:509 split ratio.

As of June 30, 2026, IDL Diagnostics AB has an Altman Z-Score of -2.87, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.